Equity Sector Funds Very High Risk Fund Manager: Nikhil Mathur
Equity Sector Funds Very High Risk
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Expert-managed portfolios tailored to your financial goals.
Estimation is based on the past performance
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | 4.86% | 8.29% | 2.49% | 1.55% | 11.88% | 20.63% | 0% | 0% | 0% | 0% | 25.63% |
| Category returns | 3.11% | 5.02% | -2.9% | -2.98% | 4.3% | 11.84% | 22.17% | 14.57% | 13.3% | 12.58% | N/A |
| Absolute returns | 4.86% | 8.29% | 2.49% | 1.55% | 11.88% | 45.67% | 0% | 0% | 0% | 0% | 78.86% |
| Rank within category | 2 | 2 | 1 | 1 | 1 | 1 | 11 | 11 | 10 | 5 | N/A |
| Total Schemes in Category | 18 | 18 | 17 | 17 | 16 | 14 | 10 | 10 | 9 | 4 | N/A |
| Sector Funds | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Yearly returns | N/A | 50.33% | 1.22% | 3.44% |
| Q1 returns | N/A | 8.5% | -6.47% | -1.46% |
| Q2 returns | N/A | 6.75% | 5.72% | 4.98% |
| Q3 Returns | N/A | 23.01% | -0.42% | N/A |
| Q4 Returns | N/A | 5.51% | 2.8% | N/A |
Expense ratio: 2.1%
Inclusive of GST
Exit load
1% on or before 30D, Nil after 30D
| Alpha | 1.34276 |
| Beta | 0.6196 |
| Sharpe Ratio | 0.377397 |
| Sortino Ratio | 0.828294 |
| R-Squared | 0.3066 |
| Tracking Error | 3.6413 |
| Downside Risk | 14.1538 |
| Std. Deviation (Annualised) | 14.0303 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Expense Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Growth | 3.89% | 3.12% | -4.73% | -4.73% | 4.68% | 25.92% | 15.59% | 0% | 19% | 6,293.14 | 1.87 | 0.39 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | 3.06% | 6.57% | -2.4% | -2.21% | 4.09% | 24.18% | 15.33% | 11.97% | 16.19% | 4,063.64 | 1.93 | 0.37 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | 3.87% | 5.79% | -3.13% | -3.32% | 5.75% | 23.99% | 13.58% | 12.4% | 14.56% | 1,055.53 | 2.28 | 0.35 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | 2.25% | 7.35% | -0.49% | -1.04% | 6.82% | 23.11% | 13.99% | 0% | 19.07% | 2,753.72 | 1.94 | 0.34 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | 1.51% | 4.46% | -1.43% | -1.12% | 3.97% | 22.31% | 12.08% | 0% | 18.11% | 858.87 | 2.30 | 0.33 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | 2.99% | 2.2% | -5.02% | -3.65% | 1.19% | 21.47% | 13.08% | 11.86% | 11.06% | 1,229.42 | 2.15 | 0.30 | Very High |
| Nippon India Pharma Fund - Growth | 1.45% | 3.58% | -2.46% | -3.47% | 2.37% | 21.41% | 12.98% | 14.09% | 19.61% | 7,898.24 | 1.82 | 0.32 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | 3.94% | 0.42% | -4.35% | -5.95% | 1.81% | 20.8% | 12.91% | 0% | 19.73% | 2,891.76 | 1.94 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | 3.18% | 3.25% | -5.64% | -4.73% | 0.37% | 19.93% | 10.15% | 0% | 15.77% | 78.30 | 2.36 | 0.28 | Very High |
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth Current | 4.86% | 8.29% | 2.49% | 1.55% | 11.88% | 0% | 0% | 0% | 25.63% | 1,976.86 | 2.10 | 0.38 | Very High |
| Instrument Allocation | Instrument | Assets % |
|---|---|---|
|
|
Domestic Equities | 98.51% |
| Cash & Cash Equivalents and Net Assets | 1.49% |
| Sector Allocation | Sector | Assets % |
|---|---|---|
| Pharmaceuticals & Biotechnology | 70.54% | |
| Healthcare Services | 27.46% | |
| Others | 1.49% | |
| Healthcare Equipment & Supplies | 0.52% |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.20% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.20% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.78% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.65% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.99% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 5.96% |
| Aster DM Healthcare Ltd. | Healthcare Services | Domestic Equities | 5.70% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.16% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.39% |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.29% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.49% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 3.10% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.76% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.37% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.34% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.24% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 2.13% |
| TREPS - Tri-party Repo | Cash & Cash Equivalents and Net Assets | 2.11% | |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.09% |
| Shilpa Medicare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.91% |
| Global Health Ltd. | Healthcare Services | Domestic Equities | 1.88% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.57% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.54% |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.54% |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.31% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 1.27% |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.24% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.07% |
| Bajaj Healthcare Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.83% |
| Laxmi Dental Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.52% |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.62% | |
| Total | 100.00% |
RETURNS
It is an Open ended scheme that primarily invests in Sector Funds.
To provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme benchmark is the BSE Health Care - TRI
It is classified as Very High Risk, suitable for investors with a Very High risk appetite.
Returns Delivered by the funds are as follows:
1-year: 11.88%
3-year: 0%
5-year: 0%
Top holdings include names such as:
The NAV is around ₹17.82 (approx.) for the HDFC Pharma and Healthcare Fund - Regular Plan - Growth.
The fund’s AUM is approximately ₹1,977 Cr.
The expense ratio for the Regular Plan is 2.1.
1% on or before 30D, Nil after 30D.
Minimum SIP starts at ₹100.
The minimum lump sum investment is ₹100. Often platforms may require higher in practice, but the statutory minimum remains the same.
You can start a SIP through:
Broker/agent platform like Sharescart.
Enter KYC details, choose the Regular Growth option, set SIP amount/frequency, and submit.
Yes. You can modify your SIP amount or frequency anytime online through the Sharescart platform.
You can redeem online via the Sharescart platform — choose the scheme, select the amount/units, and submit. Proceeds are credited to your bank account.
The fund manager: Nikhil Mathur
This fund is suitable for investors with a Very High risk tolerance.
Get personalized Portfolio Management Services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
